WO2021239165A3 - Peptide for treating coronavirus infections - Google Patents

Peptide for treating coronavirus infections Download PDF

Info

Publication number
WO2021239165A3
WO2021239165A3 PCT/CU2021/050004 CU2021050004W WO2021239165A3 WO 2021239165 A3 WO2021239165 A3 WO 2021239165A3 CU 2021050004 W CU2021050004 W CU 2021050004W WO 2021239165 A3 WO2021239165 A3 WO 2021239165A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
treatment
prevention
coronavirus infections
infections
Prior art date
Application number
PCT/CU2021/050004
Other languages
Spanish (es)
French (fr)
Other versions
WO2021239165A2 (en
Inventor
Silvio Ernesto PEREA RODRÍGUEZ
Yasser PERERA NEGRÍN
Ailyn de la Caridad RAMÓN SÁNCHEZ
Evelin CABALLERO MENÉNDEZ
Gerardo Enrique Guillen Nieto
Celia Berta FERNÁNDEZ ORTEGA
Original Assignee
Centro De Ingenieria Genetica Y Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Ingenieria Genetica Y Biotecnologia filed Critical Centro De Ingenieria Genetica Y Biotecnologia
Publication of WO2021239165A2 publication Critical patent/WO2021239165A2/en
Publication of WO2021239165A3 publication Critical patent/WO2021239165A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)

Abstract

The present invention relates to a peptide for the treatment or prevention of coronavirus infections, characterised in that it has an amino acid sequence identified as SEQ ID NO: 1. The invention further relates: to a pharmaceutical composition comprising the above-mentioned peptide, for the treatment or prevention of said infections; to a pharmaceutical combination characterised in that it includes a composition containing the peptide having the amino acid sequence identified as SEQ ID NO: 1 along with an antiviral drug, for the treatment or prevention of coronavirus infections; to the use of the peptide for manufacturing a medicine for the treatment or prevention of coronavirus infections; and to methods of treatment with said peptide.
PCT/CU2021/050004 2020-05-27 2021-05-27 Peptide for treating coronavirus infections WO2021239165A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CUCU2020-0030 2020-05-27
CU2020000030A CU20200030A7 (en) 2020-05-27 2020-05-27 PEPTIDE FOR THE TREATMENT OF INFECTIONS CAUSED BY CORONAVIRUS

Publications (2)

Publication Number Publication Date
WO2021239165A2 WO2021239165A2 (en) 2021-12-02
WO2021239165A3 true WO2021239165A3 (en) 2022-01-20

Family

ID=77411507

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2021/050004 WO2021239165A2 (en) 2020-05-27 2021-05-27 Peptide for treating coronavirus infections

Country Status (2)

Country Link
CU (1) CU20200030A7 (en)
WO (1) WO2021239165A2 (en)

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BOUHADDOU MEHDI ET AL: "The Global Phosphorylation Landscape of SARS-CoV-2 Infection", CELL, ELSEVIER, AMSTERDAM NL, vol. 182, no. 3, 28 June 2020 (2020-06-28), pages 685, XP086239962, ISSN: 0092-8674, [retrieved on 20200628], DOI: 10.1016/J.CELL.2020.06.034 *
C. SOWERS LAWRENCE ET AL: "Pharmacological approaches to the treatment of COVID-19 patients", JOURNAL OF TRANSLATIONAL SCIENCE, vol. 6, no. 6, 1 January 2020 (2020-01-01), XP055788829, Retrieved from the Internet <URL:https://oatext.com/pdf/JTS-7-394.pdf> DOI: 10.15761/JTS.1000394 *
CARRACEDO SARAH ET AL: "The landscape of COVID-19 clinical trials in Latin America and the Caribbean: assessment and challenges", REVISTA PANAMERICANA DE SALUD PUBLICA, vol. 44, 23 December 2020 (2020-12-23), US, pages 1, XP055860749, ISSN: 1020-4989, DOI: 10.26633/RPSP.2020.177 *
CRUZ LETICIA R. ET AL: "Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial", ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, vol. 4, no. 1, 12 February 2021 (2021-02-12), pages 206 - 212, XP055860666, ISSN: 2575-9108, DOI: 10.1021/acsptsci.0c00175 *
GARAY HILDA ET AL: "Characterization of low-abundance species in the active pharmaceutical ingredient of CIGB-300: A clinical-grade anticancer synthetic peptide", JOURNAL OF PEPTIDE SIENCE, vol. 24, no. 6, 1 June 2018 (2018-06-01), pages e3081, XP055860866, ISSN: 1075-2617, Retrieved from the Internet <URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpsc.3081> DOI: 10.1002/psc.3081 *
KEATING JULIE A. ET AL: "Phosphorylation events during viral infections provide potential therapeutic targets : Phosphorylation of human viruses", REVIEWS IN MEDICAL VIROLOGY, vol. 22, no. 3, 1 May 2012 (2012-05-01), GB, pages 166 - 181, XP055860706, ISSN: 1052-9276, Retrieved from the Internet <URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Frmv.722> DOI: 10.1002/rmv.722 *
MIRANDA JAMILET ET AL: "CIGB-300 Synthetic Peptide, an Antagonist of CK2 Kinase Activity, as a Treatment for Covid-19. A Computational Biology Approach", RESEARCH SQUARE, 9 August 2021 (2021-08-09), XP055860894, Retrieved from the Internet <URL:https://www.researchgate.net/publication/354230428_CIGB-300_Synthetic_Peptide_an_Antagonist_of_CK2_Kinase_Activity_as_a_Treatment_for_Covid-19_A_Computational_Biology_Approach/fulltext/612d813fc69a4e48796be152/CIGB-300-Synthetic-Peptide-an-Antagonist-of-CK2-Kinase-Activity-as-a-Treatment-for-Covid-1> [retrieved on 20211112], DOI: 10.21203/rs.3.rs-795492/v1 *
PEREA S E ET AL: "Antitumor Effect of a Novel Proapoptotic Peptide that Impairs the Phosphorylation by the Protein Kinase 2 (Casein Kinase 2)", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 64, 1 October 2004 (2004-10-01), pages 7127 - 7129, XP002399575, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-04-2086 *
VENEGAS-RODRIGUEZ R ET AL: "CIGB-258 immunomodulatory peptide: a novel promising treatment for critical and severe COVID-19 patients", MEDRXIV, 2 June 2020 (2020-06-02), XP055860741, Retrieved from the Internet <URL:https://www.medrxiv.org/content/medrxiv/early/2020/06/02/2020.05.27.20110601.full.pdf> [retrieved on 20211112], DOI: 10.1101/2020.05.27.20110601 *

Also Published As

Publication number Publication date
CU20200030A7 (en) 2022-01-13
WO2021239165A2 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
WO2005082399A3 (en) Treatment of bacterial infections
HRP20110242T1 (en) Glp-1-fc fusion protein formulation
MY138708A (en) Biaryloxymethylarenecarboxylic acids
WO2018067217A3 (en) Compositions comprising pedf-derived short peptides and uses thereof
WO2010030180A3 (en) Peptide formulations and uses thereof
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
RU2013126581A (en) STREPTokinase MUTANTS AND THEIR COVALENT MODIFIED FORMS
WO2011149964A3 (en) Methods for treating or preventing vascular graft failure
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
EP1284257A3 (en) Difluoromethylene aromatic ethers and their use as inhibitors of the glycine type-1 transporter
CA2632207C (en) Use of calcitonin for the treatment of ra
JP2006506942A5 (en)
MX2017016227A (en) Broad-spectrum anti-infective peptides.
RU2016135003A (en) NEW TYPES OF TREATMENT
EP1571155A4 (en) Peptides and medicinal compositions containing the same
MX2021009219A (en) Triamterene or nolatrexed for use in the treatment of phenylketonuria.
WO2022150654A3 (en) Antigen-binding polypeptides specific for coronaviruses and uses thereof
GB2546439A (en) Ezrin-derived peptides and pharmaceutical compositions thereof
WO2005002500A3 (en) Inhibitors of coronavirus
WO2021239165A3 (en) Peptide for treating coronavirus infections
CA2519789A1 (en) Aplidine for multiple myeloma treatment
EA202090802A1 (en) PEPTIDE COMPOSITION FOR TREATMENT OF DAMAGE ASSOCIATED WITH EXCITING NEUROTOXICITY
ATE552271T1 (en) ANTITUMOR MEDICINE, DRUG, COMPOSITION AND USE THEREOF
MX2019013874A (en) Peptides and uses therefor as antiviral agents.
WO2022184854A3 (en) Formulations of ace2 fc fusion proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21758043

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21758043

Country of ref document: EP

Kind code of ref document: A2